Mentari Therapeutics Announces Closing of Merger with InMed Pharmaceuticals and Previously Announced $490 Million Financing
Mentari Therapeutics completed its merger with InMed Pharmaceuticals and begins trading on Nasdaq today under ticker MTRI. Immediately before closing, the company raised approximately $490 million in gross private financing proceeds led by Fairmount, including conversion of $50 million of convertible notes; roughly 58.3 million shares and equivalents are outstanding post-transactions. Proceeds fund the pipeline into 2029, with initial MT-001 Phase 1 data expected mid-2027 and MT-002 on track for regulatory filing in Q1 2027 with data by year-end 2027.
Key figures
- Deal Value Usd
- 490000000
- Cash runway
- into 2029
- Mt002 filing
- Q1 2027
- Gross proceeds
- 490000000
- Mt001 data timing
- mid-2027
- Mt002 data timing
- year-end 2027
- Convertible notes converted
- 50000000
- Shares outstanding post transactions
- 58300000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.